comparemela.com

Latest Breaking News On - Biotech equity research - Page 1 : comparemela.com

Replimune Announces Appointment of Emily Hill as Chief Financial Officer

WOBURN, Mass., Sept. 19, 2023 Replimune Group, Inc. , a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the.

Arleen goldenbergChris brinzeyPhilip astley sparkeWarner chilcottFordham universityGenzyme corporationBiotech equity researchReplimune group incExchange commissionGlobenewswire incHamilton collegeTufts university school of biomedical researchSecurities exchangeEmily hillChief financialInvestor relations

StockWatch: Antitrust Fears Dampen Support for $43B Pfizer-Seagen Deal

Pfizer's planned $43 billion purchase of Seagen didn't spark the usual huge stock surge, due to antitrust review concerns.

David risingerJay olsonGregory renzaRaymond jamesAlbert bourlaZhiqiang shuGena wangEtzer daroutReni benjaminDane leoneAndrew berensDavid epsteinBiotech equity researchMerck coMerck kgaEuropean union

IDEAYA Biosciences to Participate in Investor Conferences in May 2022

/PRNewswire/ IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and.

Anupam ramaYujiro hataYigal nochomovitzCharles zhuBiotechnology equity researchBiotech equity researchBiosciences incOncology panelPanel dayBiotech synthetic lethality panelCiti biopharma virtual coChief executive officerManaging directorBiotechnology equitySynthetic lethality panelBiotech equity

Legend Biotech (LEGN) Appoints Ying Huang to its Board

Legend Biotech (LEGN) Appoints Ying Huang to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Sally wangYing huangUniversity of scienceCredit suisseMerck coColumbia universityLegend biotech corporationBofa securities incColumbia business schoolWells fargoTechnology of chinaDepartment of chemical researchBiotech corporationLegend biotechChief executive officerChief financial officer

Legend Biotech Announces Appointment of Dr Ying Huang to the Board of Directors

Legend Biotech Corporation , a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today that Dr. Ying Huang, Legend Biotech’s Chief Executive. | December 30, 2021

New jerseyUnited statesSally wangYing huangUniversity of scienceCredit suisseDrug administrationMerck coColumbia universityLegend biotech corporationEuropean medicines agencyBofa securities incColumbia business schoolDepartment of chemical researchWells fargoTechnology of china

vimarsana © 2020. All Rights Reserved.